A US and Italian review and re-analysis of existing studies on convalescent plasma treatment for COVID-19 found it may help prevent death among immunocompromised patients.
The new research published in the JAMA Network Open included eight controlled studies and 138 case studies, and found that transfusion of COVID-19 convalescent plasma was linked to a decrease in risk of fatality in immunocompromised patients, compared with control groups who were not given the plasma treatment.
These findings suggest that transfusion of COVID-19 convalescent plasma may help prevent death among immunocompromised patients whose condition does not respond to other treatments, the authors concluded.
Learn more HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Jan 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Jan 23
